This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
This is a multi-center, prospective, randomized, double-arm, single-blind, evaluator-blinded clinical trial for CKD patients referred for creation of a new arteriovenous fistula (AVF). This study will involve approximately 200 participants from up to 25 investigational sites, randomized 1:1 to treatment with the SelfWrap or the untreated AVF control (i.e. standard of care, SOC). Participants will be followed for a duration of 36 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
200
SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
AVF creation surgery without any intervention
AKDHC Bullhead City
Bullhead City, Arizona, United States
RECRUITINGAKDHC Marana Surgery Center
Marana, Arizona, United States
RECRUITINGArizona Kidney Disease & Hypertension Centers (AKDHC) Phoenix Surgery Center
Phoenix, Arizona, United States
RECRUITINGBanner University Medical Center
Tucson, Arizona, United States
RECRUITINGTallahassee Research Institute
Tallahassee, Florida, United States
RECRUITINGLutheran Medical Group
Fort Wayne, Indiana, United States
RECRUITINGSurgical Associates of Lexington
Lexington, Kentucky, United States
RECRUITINGBrigham and Women's Hospital
Boston, Massachusetts, United States
RECRUITINGUniversity of Missouri
Columbia, Missouri, United States
RECRUITINGSaint Louis University
St Louis, Missouri, United States
RECRUITING...and 12 more locations
Unassisted Maturation by 180 days
A participant who is either 1) on hemodialysis on or before day 150 and the AVF has been cannulated with two needles for at least 75% of dialysis sessions within any 4 consecutive week period to achieve the prescribed dialysis by the 180 day follow up, and did not require any facilitative endovascular or surgical intervention to achieve this, or 2) is not on hemodialysis on or before day 150, but ultrasound measurements by the 180 day follow up indicate a proximal arterial flow rate of at least 500 mL/min and a vein inner diameter of at least 5.0 mm at 5 - 8 cm from the anastomosis, and did not require any facilitative endovascular or surgical intervention through the 180 day follow up.
Time frame: Assessed at up to 6 months
Freedom from access-related adverse events through 30 days
Freedom from access-related adverse events through 30 days
Time frame: Assessed through 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.